Drug-antibody pair has promising activity in non-Hodgkin lymphoma

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute. The ongoing open-label phase 2 study presented at the American Society of Hematology meeting was designed to test the activity of brentuximab vedotin (Adcetris) in relapsed or refractory non-Hodgkin lymphoma including B-cell cancers such as diffuse large B cell lymphoma. Read more here.